Andy Parratt Email Address

Vice President Strategic Planning

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

Biotechnology product development and commercialization leader. Track record of successfully developing and launching innovative products in complex markets based upon deep customer insights. U.S., global and European affiliate experience. Thrives in fast-moving and dynamic environments. Decisive leader with proven ability to build highly effective teams focused on meeting significant, unmet customer needs. Expertise in multiple therapeutic areas including rare disease, neuroscience, cardiovascular and anti-infectives, from discovery through commercialization.